Melanotan Moles

PIGMENTATION • SKIN MONITORING

Melanotan and Moles

Moles are one of the most important melanotan-related skin changes to discuss carefully. Melanocortin activity can alter pigmentation, but a changing mole can also raise medical questions that a photo or forum thread cannot safely answer.

WHAT IS ACTUALLY DOCUMENTED

Darkening of existing nevi is recognized in regulated afamelanotide labeling.

The current FDA prescribing information for SCENESSE states that its pharmacologic effect may cause generalized increased pigmentation and darkening of pre-existing nevi and ephelides (freckles). The label recommends a full-body skin examination twice yearly to monitor existing nevi and new pigmentary lesions.

That does not prove every online MT2 product has an identical safety profile, but it shows that mole and pigment monitoring is part of the medical discussion around melanocortin agonism—not merely an internet anecdote.

WHY MOLES CAN LOOK DIFFERENT

More pigment can change visibility without telling you what a lesion is.

A mole can appear darker because the pigment within it changes, because surrounding skin becomes darker or lighter, because UV exposure changed, or because the lesion itself is evolving. A photograph alone cannot distinguish those possibilities reliably.

This is why a melanotan-related change should not be automatically categorized as either harmless or dangerous based only on appearance.

Educational dermatology-style comparison of overall pigmentation, freckles, moles and dark spots
Freckles, moles and dark spots are different findings: melanocortin activity can make several kinds of existing pigment more noticeable, but a visual comparison cannot determine whether a changing lesion is benign.

THE MELANOMA QUESTION

A darker mole is not automatically melanoma—but a changing lesion should not be dismissed.

Medical literature includes melanoma case reports after MT2 exposure. Those reports are important safety signals, but they cannot prove that MT2 caused the melanoma or estimate how large any risk might be.

UV exposure is a major confounder in some reports, and melanoma can occur for many reasons unrelated to melanotan. The responsible conclusion is therefore neither “MT2 causes melanoma” nor “there is nothing to worry about.”

A new, changing or concerning lesion should be evaluated by an appropriately qualified clinician, regardless of whether a person believes melanotan or tanning explains the change.

WHAT TO NOTICE IN A VISUAL COMPARISON

The smaller skin details can matter more than the overall tan.

A useful before-and-after image should not crop out moles or other pigmented features merely because the overall color change looks more dramatic. When permissioned photos are added to the site, we should note whether an existing mole changed in apparent darkness, whether UV exposure occurred and whether the image conditions were comparable.

MT1 VS MT2

Do not merge regulated afamelanotide data with unapproved MT2 products.

The strongest formal language about darkening of existing nevi comes from SCENESSE prescribing information for regulated afamelanotide. MT2 has a different receptor profile, research history and product context.

The afamelanotide label is useful because it confirms that pigmentary monitoring is biologically and clinically relevant. It should not be used to pretend every online product has the same composition, exposure or safety profile.

Frequently Asked Questions

Can melanotan make existing moles darker?

Darkening of pre-existing nevi is recognized in regulated afamelanotide labeling. That supports the plausibility of visible mole darkening with melanocortin activity.

Does a darker mole mean melanoma?

No. Darkening alone does not diagnose melanoma. A new or evolving lesion should still be medically assessed rather than assumed to be a harmless pigment effect.

Can a photo tell whether a mole is safe?

No. Photos can document change but cannot reliably diagnose a lesion or replace a professional skin examination.

Medical Disclaimer

This page cannot evaluate individual moles or diagnose skin cancer. New, changing or concerning pigmented lesions should be assessed by an appropriately qualified healthcare professional.

Scroll to Top